US FDA Type C Statistical Methods Meeting Granted to Review 2.5-Year OS Data for OST-HER2 in Metastatic Osteosarcoma
“We expect this Type C Statistics Methods Meeting with FDA to focus on the appropriateness of using pooled non-concurrent published historical control data, as compared with concurrent natural history data generated via OST-400, to evaluate the clinical efficacy data generated from the OST-HER2 Metastatic Osteosarcoma Trial,” said Dr. Craig Eagle, Chief Medical Advisor and member of the OS Therapies Board of Directors. “We are heartened that overall survival at the 2.5-year timepoint remained unchanged from the 2-year timepoint. We look forward to the interim 3-year overall survival data in early September 2026, that will allow for decisions on our pending Regenerative Medicine Advanced Therapy (RMAT) designation submission, FDA Rolling Review and Commissioner’s National Priority Review Voucher more rapidly to facilitate a potential Biologics License Application under the Accelerated Approval Program by year end 2026.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the